Urinary and Serum VEGF and MMP Levels in Patients Receiving Radiation Therapy for Glioblastoma Multiforme: Prospective Determination of a Predictive Value for Recurrence

Trial Information

Urinary and Serum VEGF and MMP Levels in Patients Receiving Radiation Therapy for Glioblastoma Multiforme: Prospective Determination of a Predictive Value for Recurrence

BACKGROUND

- Preliminary data generated from our pilot protocol 02-C-0064 suggests that the urinary
VEGF and MMP level at the one month follow-up time point compared to the last
on-treatment time point collection may be predictive of tumor recurrence at one year
(l).

- Note that this preliminary study included patients with all histologies.

- In an on ongoing effort to validate our results with a larger more homogeneous patient
cohort we propose to prospectively study patients undergoing radiotherapy for GBM.

OBJECTIVES

-We will determine the whether VEGF and MMP level measurements aide in predicting tumor
recurrence at 1 year.

ELIGIBILITY

-Patients seen in the radiation oncology clinic will be asked to provide samples of blood
and urine before, during and after their radiation treatment.

DESIGN

- This protocol-provides a means of acquiring blood and urine samples from patients
receiving radiation therapy for Glioblastoma multiforme (GBM).

- Patients will be stratified according to their Radiation Therapy Oncology Group (RTOG)
recursive partitioning prognostic subgroups, which includes patient age, KPS, extent of
resection and neurological function.